S&P 500   5,124.77 (-1.43%)
DOW   37,996.12 (-1.20%)
QQQ   438.21 (-1.61%)
AAPL   175.23 (+0.11%)
MSFT   421.72 (-1.45%)
META   514.06 (-1.74%)
GOOGL   158.05 (-0.85%)
AMZN   185.50 (-1.88%)
TSLA   171.46 (-1.80%)
NVDA   885.50 (-2.28%)
AMD   162.99 (-4.40%)
NIO   4.09 (-8.30%)
BABA   71.98 (-3.83%)
T   16.35 (-0.43%)
F   12.62 (-3.22%)
MU   123.26 (-3.33%)
GE   153.68 (-2.36%)
CGC   7.98 (-2.09%)
DIS   114.18 (-2.54%)
AMC   2.70 (-3.57%)
PFE   26.02 (-1.21%)
PYPL   64.83 (-1.47%)
XOM   121.50 (-0.24%)
S&P 500   5,124.77 (-1.43%)
DOW   37,996.12 (-1.20%)
QQQ   438.21 (-1.61%)
AAPL   175.23 (+0.11%)
MSFT   421.72 (-1.45%)
META   514.06 (-1.74%)
GOOGL   158.05 (-0.85%)
AMZN   185.50 (-1.88%)
TSLA   171.46 (-1.80%)
NVDA   885.50 (-2.28%)
AMD   162.99 (-4.40%)
NIO   4.09 (-8.30%)
BABA   71.98 (-3.83%)
T   16.35 (-0.43%)
F   12.62 (-3.22%)
MU   123.26 (-3.33%)
GE   153.68 (-2.36%)
CGC   7.98 (-2.09%)
DIS   114.18 (-2.54%)
AMC   2.70 (-3.57%)
PFE   26.02 (-1.21%)
PYPL   64.83 (-1.47%)
XOM   121.50 (-0.24%)
S&P 500   5,124.77 (-1.43%)
DOW   37,996.12 (-1.20%)
QQQ   438.21 (-1.61%)
AAPL   175.23 (+0.11%)
MSFT   421.72 (-1.45%)
META   514.06 (-1.74%)
GOOGL   158.05 (-0.85%)
AMZN   185.50 (-1.88%)
TSLA   171.46 (-1.80%)
NVDA   885.50 (-2.28%)
AMD   162.99 (-4.40%)
NIO   4.09 (-8.30%)
BABA   71.98 (-3.83%)
T   16.35 (-0.43%)
F   12.62 (-3.22%)
MU   123.26 (-3.33%)
GE   153.68 (-2.36%)
CGC   7.98 (-2.09%)
DIS   114.18 (-2.54%)
AMC   2.70 (-3.57%)
PFE   26.02 (-1.21%)
PYPL   64.83 (-1.47%)
XOM   121.50 (-0.24%)
S&P 500   5,124.77 (-1.43%)
DOW   37,996.12 (-1.20%)
QQQ   438.21 (-1.61%)
AAPL   175.23 (+0.11%)
MSFT   421.72 (-1.45%)
META   514.06 (-1.74%)
GOOGL   158.05 (-0.85%)
AMZN   185.50 (-1.88%)
TSLA   171.46 (-1.80%)
NVDA   885.50 (-2.28%)
AMD   162.99 (-4.40%)
NIO   4.09 (-8.30%)
BABA   71.98 (-3.83%)
T   16.35 (-0.43%)
F   12.62 (-3.22%)
MU   123.26 (-3.33%)
GE   153.68 (-2.36%)
CGC   7.98 (-2.09%)
DIS   114.18 (-2.54%)
AMC   2.70 (-3.57%)
PFE   26.02 (-1.21%)
PYPL   64.83 (-1.47%)
XOM   121.50 (-0.24%)

Recursion Pharmaceuticals (RXRX) Competitors

$8.54
-0.38 (-4.26%)
(As of 12:39 PM ET)

RXRX vs. SANA, PTCT, NMRA, TWST, DNA, KYMR, SDGR, FUSN, INBX, and VCEL

Should you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Sana Biotechnology (SANA), PTC Therapeutics (PTCT), Neumora Therapeutics (NMRA), Twist Bioscience (TWST), Ginkgo Bioworks (DNA), Kymera Therapeutics (KYMR), Schrödinger (SDGR), Fusion Pharmaceuticals (FUSN), Inhibrx (INBX), and Vericel (VCEL). These companies are all part of the "medical" sector.

Recursion Pharmaceuticals vs.

Recursion Pharmaceuticals (NASDAQ:RXRX) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends, valuation and community ranking.

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 20.0% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 34.9% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Recursion Pharmaceuticals had 10 more articles in the media than Sana Biotechnology. MarketBeat recorded 13 mentions for Recursion Pharmaceuticals and 3 mentions for Sana Biotechnology. Recursion Pharmaceuticals' average media sentiment score of 0.68 beat Sana Biotechnology's score of 0.62 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Recursion Pharmaceuticals
4 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Sana Biotechnology
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Recursion Pharmaceuticals received 9 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 50.00% of users gave Recursion Pharmaceuticals an outperform vote while only 47.83% of users gave Sana Biotechnology an outperform vote.

CompanyUnderperformOutperform
Recursion PharmaceuticalsOutperform Votes
20
50.00%
Underperform Votes
20
50.00%
Sana BiotechnologyOutperform Votes
11
47.83%
Underperform Votes
12
52.17%

Sana Biotechnology has lower revenue, but higher earnings than Recursion Pharmaceuticals. Sana Biotechnology is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Recursion Pharmaceuticals$44.58M46.95-$328.07M-$1.55-5.75
Sana BiotechnologyN/AN/A-$283.26M-$1.47-6.37

Recursion Pharmaceuticals currently has a consensus price target of $12.75, indicating a potential upside of 42.94%. Sana Biotechnology has a consensus price target of $11.67, indicating a potential upside of 24.64%. Given Recursion Pharmaceuticals' higher probable upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Sana Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Recursion Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40
Sana Biotechnology
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Sana Biotechnology has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -735.99%. Recursion Pharmaceuticals' return on equity of -72.88% beat Sana Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
Recursion Pharmaceuticals-735.99% -72.88% -50.89%
Sana Biotechnology N/A -88.36%-47.89%

Recursion Pharmaceuticals has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500.

Summary

Recursion Pharmaceuticals beats Sana Biotechnology on 9 of the 17 factors compared between the two stocks.

Get Recursion Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RXRX vs. The Competition

MetricRecursion PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$2.01B$2.70B$4.93B$7.71B
Dividend YieldN/A2.26%2.96%3.91%
P/E Ratio-5.7518.59186.6914.46
Price / Sales46.95357.392,339.9794.10
Price / CashN/A145.1736.0531.39
Price / Book4.513.964.684.40
Net Income-$328.07M-$42.50M$103.35M$215.04M
7 Day Performance0.56%-0.87%-0.56%-0.61%
1 Month Performance-15.37%-0.67%-0.25%0.14%
1 Year Performance45.04%24.83%18.42%11.93%

Recursion Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SANA
Sana Biotechnology
2.4759 of 5 stars
$8.82
-12.8%
$11.67
+32.3%
+156.4%$1.94BN/A-6.00328Positive News
Gap Down
PTCT
PTC Therapeutics
2.6672 of 5 stars
$28.40
-0.7%
$33.53
+18.1%
-43.5%$2.18B$937.82M-3.40988Analyst Report
NMRA
Neumora Therapeutics
1.1969 of 5 stars
$13.77
-1.2%
$22.57
+63.9%
N/A$2.19BN/A0.00124Positive News
TWST
Twist Bioscience
2.494 of 5 stars
$32.92
-4.3%
$37.40
+13.6%
+140.1%$1.90B$245.11M-9.12919Analyst Report
DNA
Ginkgo Bioworks
1.316 of 5 stars
$1.04
-7.1%
$2.20
+111.5%
-21.6%$2.24B$251.46M-2.211,218News Coverage
KYMR
Kymera Therapeutics
0.2724 of 5 stars
$37.64
-4.5%
$39.89
+6.0%
+18.7%$2.30B$78.59M-14.94187Short Interest ↑
Analyst Revision
News Coverage
SDGR
Schrödinger
3.6629 of 5 stars
$25.08
-4.7%
$43.50
+73.4%
-1.2%$1.81B$216.67M39.81867News Coverage
FUSN
Fusion Pharmaceuticals
0.8031 of 5 stars
$21.29
+0.2%
$20.25
-4.9%
+435.3%$1.80B$2.07M-14.48101Analyst Revision
INBX
Inhibrx
2.0133 of 5 stars
$34.85
-0.1%
$27.00
-22.5%
+102.8%$1.65B$1.80M-6.93166Short Interest ↑
Positive News
VCEL
Vericel
0.614 of 5 stars
$51.26
-3.1%
$46.40
-9.5%
+58.5%$2.48B$197.52M-569.49314Short Interest ↑

Related Companies and Tools

This page (NASDAQ:RXRX) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners